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Although inflammatory bowel diseases (IBDs) are 
associated with a high risk of colon carcinogene-
sis, the mechanisms underlying this association 
have yet to be fully elucidated. Intestinal micro-
biota appear to be a key pathogenic trigger in the 
development of IBD, a fact which implicates a 
contribution of innate and adaptive immune re-
sponses in which Toll-like receptors (TLRs) may 
function as primary sensors of microbial coloniza-
tion. Most of these receptors, as well as all the re-
ceptors for the proinflammatory cytokines of the 
IL-1 family, use a common signal transduction 
molecule called myeloid differentiation factor 88 
(MyD88). Association of MyD88 with the intra-
cellular Toll-like–IL-1 resistance domain of the 
receptors results in activation of the NF-B and 
AP-1 signaling pathways, leading to the initiation 
of the proinflammatory response. Although 
Myd88/ mice are viable and are apparently 
normal in the absence of infections, early studies 
(Araki et al., 2005) highlighted an important role 
of MyD88 in maintenance of intestinal homeo-
stasis, in that  irradiation or administration of 
dextran sodium sulfate (DSS) resulted in severe 
ulceration  and  inflammation,  accompanied  by 
bleeding and high lethality. Several studies dem-
onstrated that recognition of commensal luminal 
bacteria by TLRs is crucial for colonic epithelial 
cell regeneration upon DSS injury (Rakoff- 
Nahoum et al., 2004; Pull et al., 2005; Brown   
et  al.,  2007).  The  ability  of  MyD88  to  signal 
through NF-B suggests that its role in control-
ling mucosal homeostasis may be dependent on 
the  activity  of  this  transcription  factor  in   
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Signaling through the adaptor protein myeloid differentiation factor 88 (MyD88) promotes 
carcinogenesis in several cancer models. In contrast, MyD88 signaling has a protective role 
in the development of azoxymethane (AOM)/dextran sodium sulfate (DSS) colitis- 
associated cancer (CAC). The inability of Myd88/ mice to heal ulcers generated upon 
injury creates an altered inflammatory environment that induces early alterations in  
expression of genes encoding proinflammatory factors, as well as pathways regulating cell 
proliferation, apoptosis, and DNA repair, resulting in a dramatic increase in adenoma  
formation and progression to infiltrating adenocarcinomas with frequent clonal mutations 
in the -catenin gene. Others have reported that toll-like receptor (Tlr) 4–deficient mice 
have a similar susceptibility to colitis to Myd88-deficient mice but, unlike the latter, are 
resistant to CAC. We have observed that mice deficient for Tlr2 or Il1r do not show a 
differential susceptibility to colitis or CAC. However, upon AOM/DSS treatment Il18/ and 
Il18r1/ mice were more susceptible to colitis and polyp formation than wild-type mice, 
suggesting that the phenotype of Myd88/ mice is, in part, a result of their inability to 
signal through the IL-18 receptor. This study revealed a previously unknown level of  
complexity surrounding MyD88 activities downstream of different receptors that impact 
tissue homeostasis and carcinogenesis.
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T-bet/ and Rag2/ ulcerative colitis mice (Garrett et al., 
2009). Nevertheless, the role of MyD88 in chronic colitis- 
induced cancer remained to be studied.
Unlike previous studies in other genetic or chemical carci-
nogenesis models, in this paper we describe a protective role of 
MyD88 in the development of the colonic tumors that develop 
after AOM/DSS treatment. The inability of Myd88/ mice to 
heal ulcers generated upon injury creates an altered inflamma-
tory environment that exacerbates the mutation rate in mucosal 
epithelial cells and results in augmented adenoma formation and 
cancer progression. We also report that mice deficient in Il18 
and Il18r1 display upon AOM/DSS treatment an increased sus-
ceptibility to colitis and polyp formation, with a similar but not 
identical molecular profile to that observed in Myd88/ mice, 
suggesting that the susceptibility of the latter mice to colitis and 
colitis-associated cancer (CAC) is in part a result of their inability 
to signal through the IL-18 receptor.
RESULTS
Myd88/ mice show increased susceptibility to develop 
colonic tumors after AOM/DSS administration
Myd88/ mice are highly susceptible to the development of 
colitis induced by irradiation or DSS as a result of reduced ability 
to repair the mucosal integrity after injury with significant mor-
bidity and mortality (Rakoff-Nahoum et al., 2004; Araki et al., 
2005). In our studies, we were able to maintain survival of the 
majority of the Myd88/ mice after DSS treatment by admin-
istering wet feed and saline injections in case of dehydration. 
Myd88/ and WT mice were systemically injected with the 
carcinogen AOM followed by induction of colitis by DSS ad-
ministration in the drinking water in 5-d cycles. As expected, a 
high frequency of intestinal bleeding resulting in anemia, marked 
diarrhea, and a decrease in the length of the colons was observed 
in Myd88/ mice (Fig. 1, A–D). Macroscopic analysis of 
the colons at day 60 after AOM administration indicated a 
much higher mean number of colonic polyps 
in Myd88/ mice than in WT B6 mice associated 
with a modest increase in local inflammation score 
(Fig. 1, E and F). Furthermore, unlike WT mice, 
the  majority  of  Myd88/  mice  presented   
enterocyte  survival.  Mice  in  which  the  canonical  pathway   
of NF-B activation is completely blocked in enterocytes 
(by tissue-specific deletion of Nemo or both Ikka and Ikkb) spon-
taneously developed colitis that was, however, prevented in mice 
that were also systemically deficient for MyD88, suggesting that 
the lack of NF-B renders the enterocytes susceptible to inflam-
matory mediators produced by nonepithelial cells triggered by 
ligands of TLRs or IL-1Rs (Nenci et al., 2007). Mice with   
enterocyte-specific depletion of Ikkb did not spontaneously   
develop colitis and were not more susceptible to DSS-induced 
colitis but developed a lower number of colonic polyps than 
WT mice when treated with the chemical carcinogen azoxy-
methane (AOM) followed by DSS administration (Greten et al., 
2004). When Ikkb was specifically deleted in myeloid cells, the 
number of polyps was not affected but their size was decreased, 
suggesting that NF-B–dependent myeloid-derived factors   
promote tumor growth (Greten et al., 2004).
Recently, several studies highlighted an important role of 
MyD88 in tumor promotion. In the two-stage cutaneous chem-
ical carcinogenesis model, MyD88 has a promoting role in   
cancer, as indicated by inhibition of tumor induction in MyD88 
genetically deficient mice compared with WT mice (Swann   
et al., 2008). Similarly, in the diethylnitrosamine-induced liver 
cancer model, MyD88 deficiency diminished the development 
of hepatic cancer in male mice via inhibition of IL-6 production 
(Naugler et al., 2007). Additionally, in the ApcMin/+ mouse model 
of spontaneous intestinal tumorigenesis, MyD88 signaling con-
tributed to adenoma growth and progression. Furthermore, re-
duced colon tumor growth was observed in Myd88/ mice 
subjected to multiple injections of AOM in comparison with 
WT controls (Rakoff-Nahoum and Medzhitov, 2007). MyD88 
signaling was also shown to be required for AOM-enhanced 
colon carcinogenesis in Il10/ mice (Uronis et al., 2009). Defi-
ciency in MyD88 was found not to affect the spontaneous de-
velopment of colonic dysplasia and rectal adenocarcinoma in 
Figure 1.  Myd88/ mice develop colonic polyps 
after AOM/DSS administration. Cohorts of 8–10 WT 
and Myd88/ mice per group were injected i.v. with AOM 
on day 0 followed by two DSS cycles administered in 
drinking water. At the completion of the first DSS cycle, 
mice were monitored for bleeding (A) and diarrhea (B).  
60 d after AOM administration, hematocrits were mea-
sured (C), mice were euthanized and colons were resected 
and measured (D), and macroscopic polyps were counted (E). 
Colon sections were fixed in formalin and stained with 
hematoxylin-eosin. Sections were analyzed for inflamma-
tion degree (F), extent of ulceration (G), and squamous 
metaplasia (H). The data shown correspond to a represen-
tative experiment out of four performed. Data represent 
means ± SE (and in some panels also individual mice  
results). *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 207, August 2, 2010 
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corresponding WT or Myd88+/ littermates (Fig. S1). These 
data suggest that MyD88 deficiency has a direct effect on the 
susceptibility of the mice to colitis and carcinogenesis that is 
likely not a result of broad changes in the environment or in the 
type of commensal microbiota.
Previous studies have shown that Myd88/ mice are resis-
tant to different chemical or genetic models of carcinogenesis, 
extensive active ulcers and squamous metaplasia localized mainly 
in the last third of the distal colon (Fig. 1, G and H). To limit the 
variability of the intestinal commensal microbiota in the immu-
nodeficient Myd88/ mice compared with the WT mice, the 
experiments were repeated using littermates from Myd88+/ 
parents. Severe colitis and increased frequency of tumor growth 
were obtained when Myd88/ mice were compared with their 
Figure 2.  AOM/DSS treatment of Myd88/ mice results in decreased proliferation and enhanced apoptosis of colonic epithelial cells and 
increased expression of mitogenic, angiogenic, and pro-tumorigenic genes. Cohorts of 10 WT and Myd88/ mice were injected i.v. with AOM on 
day 0 followed by 3 d of DSS administration in drinking water. Thereafter, colons were resected, fixed in formalin, and sections were stained with Ki67 or 
ApopTag antibodies. Photomicrographs of representative sections from the respective groups are shown at 400× magnification (A). The number of prolif-
erating cells per crypt and the number of apoptotic cells was determined by counting 20 consecutive crypts/section (B and C). Gene expression profile in 
colon tissue after AOM/DSS treatment was analyzed by real-time RT-PCR. The gene expression was normalized to Gapdh levels, and the expression of 
each gene relative to untreated WT mice is depicted (D). The data shown in A–D correspond to a representative experiment out of two performed. Data 
represent means ± SE. *, P < 0.05; **, P < 0.01; ***, P < 0.001.1628 MyD88 and IL-18 in colitis-associated cancer | Salcedo et al.
from damage induced by DSS or irradiation. Basal colonic 
mucosal epithelial cell proliferation was shown to be increased 
in untreated Myd88/ and Tlr4/ mice, but the mucosal 
repair after injury by irradiation in Myd88/ mice (Rakoff-
Nahoum et al., 2004) or by DSS in Tlr4/ mice (Fukata et al., 
2005) was impaired, which is consistent with the reduced 
ability of these mice to repair their mucosa after injury. We 
observed that colonic mucosal epithelial cell proliferation, as 
indicated  by  Ki67  staining,  was  decreased  approximately 
threefold at the third day of DSS administration after AOM 
treatment in Myd88/ mice compared with WT controls 
(Fig. 2, A and B), whereas apoptosis was increased (Fig. 2,   
A and C). Thus, the inability of epithelial cells to proliferate 
efficiently in Myd88/ mice during the repair reaction after 
DSS-induced mucosal injury is likely to contribute to the   
severe mucosal erosion and bleeding observed in these animals.
The decreased reactive epithelial cell proliferation and   
increased apoptosis was difficult to reconcile with the increased 
susceptibility of Myd88/ mice to the development of polyps 
after AOM/DSS treatment. Thus, gene expression profiling 
of total colon in AOM/DSS-treated Myd88/ and WT mice 
was performed (Fig. S3) and expression of cell proliferation–
associated genes was compared. Although the use of RNA 
from total tissues in microarray gene expression analysis has the 
limitation of failing to identify the cellular types expressing 
the different genes, it is the preferred approach in many studies, 
it avoids the modification of gene expression taking place 
during cell purification procedure, and 
it is been shown to be able to pro-
vide important information regard-
ing  the  main  molecular  pathways 
affected in different experimental or 
pathological conditions. The epider-
mal growth factor receptor (EGFR), 
Met,  and  -catenin  pathways  and 
their  ligands  were  observed  to  be 
preferentially induced in Myd88/ 
mice  after  AOM/DSS  administra-
tion (Fig. S4), indicating that com-
pensatory mechanisms are apparently 
including intestinal carcinogenesis in Apcmin/+ mice, Il10/ 
mice, or after repeated treatment with the carcinogen AOM 
(Rakoff-Nahoum and Medzhitov, 2007; Uronis et al., 2009). 
Thus, to exclude the possibility that our apparently contradic-
tory results in the AOM/DSS system were a result of differ-
ences in our animal colony conditions or of genetic drifting in 
our Myd88/ mice, we subjected Myd88/ mice to repeated 
treatments of AOM administration and, in agreement with the 
previously reported data, we observed a decreased incidence of 
colonic tumor (Fig. S2). In contrast, we observed that adminis-
tration of DSS alone unexpectedly elicited the formation of   
colonic tumors in a small proportion of Myd88/ mice but not 
in WT mice, although the difference did not reach statistical 
significance (Fig. S2). Thus, it is possible to speculate that the 
inflammatory effect elicited by exposure of DSS is sufficient to 
induce a low frequency of colonic tumors in Myd88/ mice 
and that this inflammation enhanced their susceptibility to the 
carcinogenic effects of AOM, whereas the generation of tumors 
after administration of AOM in the absence of DSS-induced 
inflammation required intact signaling through Myd88.
Myd88/ mice exhibit decreased colonic epithelial cell 
proliferation and enhanced apoptosis after AOM/DSS 
administration, triggering mucosal ulceration associated 
with local inflammation
Previous studies indicated that engagement of TLR by com-
mensal microbiota is required to protect the intestinal mucosa 
Figure 3.  AOM/DSS treatment  
enhances mucosal expression of COX-2 
and phospho-STAT3 in Myd88/ mice. 
Cohorts of 5–10 mice were subjected to 
treatment as indicated in Fig. 2. At day 3 of 
DSS administration, colons were resected 
and fixed in formalin or snap frozen for 
protein extraction. Tissue sections were 
stained for COX-2 and pSTAT3. Photomicro-
graphs of representative sections from the 
respective groups are shown at 200× (A). 
Protein extracts were analyzed by Western 
blotting for COX-2, STAT3, and pSTAT3 expres-
sion. Gapdh was used as a control (B). The 
data shown in A and B correspond to a repre-
sentative experiment out of two performed.JEM VOL. 207, August 2, 2010 
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were also up-regulated in treated Myd88/ mice (Fig. 2 D). 
Importantly, increased expression of antibacterial peptides, 
including angiogenin 4 and Relm-, were also induced in 
AOM/DSS-treated Myd88/ mice, possibly in response to 
bacterial translocation to the colonic mucosa (Fig. 2 D).
It is of note that expression of genes associated with promo-
tion of colon tumorigenesis, including those encoding amphi-
regulin, Wnt-5a, Wisp1, HIF-1, COX-2, MMP-10, and 
activated in the abortive attempt to maintain the integrity of 
the colonic mucosa. In addition, mRNA expression of cytokine 
genes and genes of mitogenic responsiveness involved in wound 
healing, such as those encoding IL-6, IL-11, EGFR ligands 
including amphiregulin and heparin-binding EGF, as well as 
factors involved in tissue remodeling and angiogenesis including 
matrix metalloproteinase (MMP) 10, angiogenin 4, cycloox-
ygenase 2 (COX-2), and hypoxia-inducible factor (HIF)-1, 
Figure 4.  Increased DNA damage is elicited by AOM/DSS treatment in Myd88/ mice compared with WT mice. RNA was extracted from cohorts of  
10 WT or Myd88/ mice per group treated with AOM/DSS and from cohorts of six nontreated WT or Myd88/ mice/group. Samples were processed using the  
Affymetrix microarray platform, and analyzed using the Ingenuity Pathway and Cluster and TreeView Programs. A significant decrease in DNA repair gene expres-
sion profile was observed in Myd88/ mice after AOM/DSS treatment compared with treated WT mice (A and B). The data shown in A and B were obtained from 
the microarray experiment that was performed once. The pattern of DNA repair gene expression was subsequently confirmed using real-time RT-PCR. The gene 
expression was normalized to Gapdh levels, and the expression of each gene relative to untreated WT mice is depicted. One out of two representative experiments is 
shown (C). Data represent means ± SE. **, P < 0.01; ***, P < 0.001. For analysis of -catenin mutations, cohorts of 15–20 mice/group were subjected to AOM/DSS 
treatment (two DSS/cycles). 60 d after AOM administration, individual polyps were resected, and DNA was extracted and analyzed for mutation of -catenin using 
specific primers for exon 3. The numbers of polyps exhibiting point mutations at positions 33, 34, 37, and 41 in exon 3 are indicated in the scheme by the stars (D). 
The polyps analyzed for -catenin mutations were obtained from multiple experiments and each polyp was sequenced for mutations once.1630 MyD88 and IL-18 in colitis-associated cancer | Salcedo et al.
cell  proliferation, 
and enhanced apop-
tosis, was also asso-
ciated  with  the 
induction  of  com-
pensatory pathways 
of tissue self-renewal 
and wound repair. However, this was not fully effective in con-
trolling the mucosal damage and resulted in a chronic in-
flammatory state promoting tumor formation.
AOM/DSS treatment results in decreased expression  
of mismatch DNA repair genes, which correlates with  
the high frequency of -catenin mutations and colon 
adenocarcinoma formation in Myd88/ mice
AOM/DSS-induced colitis in Myd88/ mice was observed 
to be associated with a coordinated down-regulation of genes 
involved in mismatch DNA repair, including poly ADP-ribose 
polymerase (Parp) family members Parp1 and Parp2, Fancb 
(Fanconi anemia complementation group B), Fancf, Dclre1a 
(DNA cross-link repair 1A), msh2, msh3, mlh1, and bml, as 
well as genes involved in double-strand DNA repair including 
ATM (ataxia telangiectasia mutated) and ATR (ataxia telan-
giectasia and Rad3 related; Fig. 4). Low levels of DNA mis-
match  repair  gene  expression  might  imply  higher  genetic 
instability in the epithelial cells after DNA damage induced 
by AOM or inflammatory mediators with increased frequency 
of oncogenic mutations in Myd88/ mice. Indeed, a screen 
for -catenin mutations in exon 3 revealed a much higher 
frequency of mutations in the polyps resected from Myd88/ 
mice (15 out of 45 sequenced) than in those from WT mice 
(no mutation detected in 20 resected polyps; Fig. 4 D). Im-
portantly, the detected -catenin mutations were at codons 
33, 34, 37, and 41, all of which encode functional residues for 
phosphorylation by GSK3 or for ubiquitination and, therefore, 
control  -catenin  degradation.  Previous  studies  indicated 
STAT-3, were induced in Myd88/ mice early in response to 
colonic injury, which could potentially also drive the formation 
of colonic polyps (Fig. 2 D). After treatment, elevated expression 
of COX-2 and pSTAT3 proteins were also detected in 
Myd88/ versus WT mice, as shown by immunohistological 
staining and Western blot analysis (Fig. 3). In Myd88/ mice, 
COX-2 expression was observed mainly in the areas where   
inflammatory cells infiltrated the ulcerated areas of the mucosa, 
although no colocalization of COX-2 and macrophage staining 
was observed (Fig. 3 and not depicted). Phospho-STAT3 was 
strongly and rapidly expressed in the nuclei of most epithelial 
cells of Myd88/ mice upon AOM/DSS treatment (as well as 
in many stromal and infiltrating cells). In WT mice, pSTAT3 
was present only in few infiltrating cells and was not expressed 
on epithelial cells until much later when it was present in the   
epithelial cells involved in polyp formation but not in the sur-
rounding normal mucosa (Fig. 3 and not depicted). A reduced 
expression of signaling Smads and enhanced expression of sup-
pressive Smads suggest that TGF- signaling might be inhibited 
in the colon of AOM/DSS-treated Myd88/ mice (unpub-
lished data). Also, Rb expression was reduced, whereas that of 
E2f was enhanced (Fig. 4).
After AOM/DSS treatment, Ifng was up-regulated in WT 
but not in Myd88/ colon (Fig. 2 D). Compared with the 
WT mice, both the basal level and that after AOM/DSS   
of  IFN-responsive  genes,  including  indoleamine-pyrrole   
2,3-dioxygenase (Indo), Irf8 (IFN regulatory factor 8), and Igtp 
(IFN-–induced GTPase), were decreased in Myd88/ mice. 
In addition, the induction upon AOM/DSS treatment of other 
IFN-responsive genes, including Irf4 (IFN regulatory factor 4), 
Ifi30 (IFN- inducible protein 30), and Irf2bp2 (IFN regulatory factor 
2 binding protein 2), was reduced in Myd88/ mice (Fig. 2 D 
and not depicted).
Overall, these data indicate that in Myd88/ mice the 
response to the mucosal damaged induced by AOM/DSS, 
which is characterized by diminished IFN responses, decreased 
Figure 5.  AOM/DSS treatment induces 
increased frequency of colonic  
adenocarcinomas in Myd88/ mice.  
Cohorts of 15 Myd88/ mice and 20 WT mice 
were injected i.v. with AOM on day 0 followed 
by a single DSS cycle. Animals were monitored 
during 6 mo after treatment for survival  
(P = 0.0005, WT vs. Myd88/; A). All the colons 
were analyzed for polyps when mice reached 
any of the end points for euthanasia or at the 
completion of the experiment (***, P < 0.001; B).  
Colon sections were fixed and stained with 
hematoxylin-eosin. 17 polyps from the WT 
group and 52 polyps from Myd88/ knockout 
mice were analyzed histologically. Photomicro-
graphs of representative sections from the 
respective groups are shown at 20× (C). The 
percentage of mice developing adenocarcino-
mas is indicated (D). Photomicrographs of 
representative adenocarcinomas from multiple 
of those that developed in Myd88/ mice are 
shown at 40× magnification (E–G). The data 
shown in this figure were obtained from a 
single experiment performed treating the mice 
with one DSS cycle but closely mimic the data 
obtained from two other independent experi-
ments with mice treated with two DSS cycles 
that are shown in Fig. S1.JEM VOL. 207, August 2, 2010 
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mice (Fig. S5, E and F). AOM/DSS-treated Il18r1/ mice 
also showed more severe colitis than WT mice as manifested 
by weight loss, bleeding, and lethality (Fig. S6 and not depicted). 
Similarly to the Myd88/ mice, a significant decrease of the 
expression of several DNA damage repair genes (Atm, Atr, 
Msh2, and Parp1) was observed in AOM/DSS-treated Il18/ 
mice (Fig. 7). Most importantly, all the Il18/ and Il18r1/ 
mice exhibited increased numbers of intestinal polyps after 
four DSS cycles (Fig. 6 B and Fig. S6 C), mimicking the effects 
observed in Myd88/ mice after exposure to two DSS cycles. 
As in Myd88/ mice, -catenin mutation was observed in 
polyps from Il18/ mice but not from WT mice (unpub-
lished data). Il1r1/ mice developed similar numbers of   
polyps to the WT controls. It is of note that Myd88/ mice 
developed a higher number of polyps after the second DSS 
cycle than both Il18/ and Il18r1/ mice after four DSS 
cycles (Fig. 6, B and C; and Fig. S6 C). Additionally, increased 
frequency of tumor growth was observed when Il18/ mice 
were compared with their corresponding WT or Il18+/  
littermates (Fig. 6 E). In contrast, there was no difference in 
the number of polyps among Il1r/ and their corresponding 
littermates (Fig. 6 D).
To evaluate whether common mediators are associated 
with the susceptibility of Il18- and MyD88-deficient mice to 
colitis, we compared the levels of expression of genes involved 
in inflammation and wound healing that we had observed to 
be differentially regulated in Myd88/ mice. As observed in 
Myd88/ mice, increased Il6, Il11, Mmp10, and Areg mRNA 
expression, as well as enhanced levels of pSTAT-3, was observed 
in the colonic mucosa of Il18/ mice. After AOM/DSS 
treatment, Ifng was up-regulated in WT but not in Il18/ 
colon (Fig. 7 A). Also, a decrease in the IFN-dependent gene 
Indo was found in Il18/ mice (Fig. 7, A–C). However, unlike 
that seen in Myd88/ mice, no decreased proliferation rate 
or apoptosis in enterocytes was observed in Il18/ mice after 
AOM/DSS treatment (Fig. 7 D). In addition, Cox2 expression 
was up-regulated in Myd88/ mice after AOM/DSS treatment 
but not in Il18/ mice (Fig. 7 C).
that functional mutations in the -catenin gene play a critical 
role in the progression of colon carcinogenesis (Yamada et al., 
2003). We therefore performed long-term experiments to 
evaluate if the adenomas that developed in MyD88 knockout 
mice  progressed  into  adenocarcinomas.  For  this  purpose, 
mice were injected with AOM at day 0, followed by a single 
DSS cycle from days 7 to 12, and the animal were followed 
for 6 mo. Significant decreases in survival were observed in 
Myd88/ mice in contrast to the WT group (P = 0.0005; 
Fig. 5 A). Myd88/ mice exhibited a marked increase in the 
number of polyps at the time of euthanasia in contrast to the 
WT control group (mean polyps: 11.16 ± 5.6 in Myd88/ 
vs 0.89 ± 0.84 in WT; P < 0.0001; Fig. 5 B). Myd88/ mice 
exhibited extensive, large, and confluent adenomas in con-
trast to WT (Fig. 5 C). 67% of the Myd88/ mice developed 
adenocarcinomas characterized by formation of acinar struc-
tures within the mucosa and invasion into the submucosa, 
and even into the serosa, in some cases, with occasional   
formation of mucin deposits (Fig. 5, D–G).
Il18/ and Il18r1/ mice partially mimic  
the susceptibility of Myd88/ to AOM/DSS induction  
of colitis and colon cancer
MyD88 mediates signaling for the IL-1 family receptors and 
TLRs. To identify the upstream MyD88-coupled receptors 
involved in mediating susceptibility to colitis and colon car-
cinogenesis, we examined the responses elicited by AOM/
DSS treatment in either Il1r1/ or Il18/ mice. Cohorts of 
Myd88/, Il18/, or Il1r1/ mice and their respective 
controls were treated with AOM and subjected to two or 
four DSS cycles. Compared with WT C57BL6J controls and 
Il1r/ animals, Il18/ mice displayed significantly more in-
testinal bleeding after DSS administration, mimicking, although 
to a lesser degree, the phenotype observed in Myd88/ mice 
(Fig. 6 A). As result of increased intestinal bleeding, lower 
hematocrits were displayed by Il18/ and Myd88/ mice 
(unpublished data). In addition, in acute colitis induced by a 
5-d treatment with 5% DSS the Il18/ mice showed higher 
bleeding, diarrhea, and inflammation histology score as well 
as shorter colon than WT controls (Fig. S5, A–D). The   
histology was characterized by an increase in ulceration, rem-
iniscent of the pathology observed in DSS-treated Myd88/ 
Figure 6.  Il18 deficiency mimics MyD88 deficiency suscep-
tibility to polyp formation. Cohorts of 6–20 mice/group were 
subjected to AOM/DSS treatment as depicted by the scheme. At the 
end of the first DSS cycle, mice were analyzed for bleeding (A).  
100 d after AOM administration, the Il1r1/, Il18/, and their 
corresponding controls were euthanized and colonic polyps were 
counted (B). For comparison, Myd88/ mice were tested simulta-
neously. Because of their susceptibility to the treatment, the num-
ber of polyps was scored at the completion of the second DSS 
cycle (C). The data shown in A–C correspond to a representative 
experiment out of three performed. Il18/ and Il1r/ mice and 
their corresponding heterozygote and WT littermates were sub-
jected to AOM/DSS treatment as indicated by the scheme. At the 
completion of the experiment, the number of colonic polyps was 
counted (D and E). The data shown in D and E correspond to a 
representative experiment out of two performed using littermate 
controls. Data represent means ± SE. **, P < 0.01; ***, P < 0.001.1632 MyD88 and IL-18 in colitis-associated cancer | Salcedo et al.
mechanism involves an increased proliferation of epithelial 
cells that was shown to be defective in Tlr4/ mice and that 
we now find to also be reduced by almost threefold in AOM/
DSS-treated Myd88/ mice. However, this reduced epithelial 
cell proliferation was, at 3 d after DSS treatment initiation, 
already associated with an up-regulation of many of the   
molecular pathways that are involved in induction and progres-
sion into the cell cycle. This seems to indicate an aborted at-
tempt to respond to the damage with increased proliferation. 
It is not yet obvious what the mechanism is that limits the 
ability of the cells to proliferate, but it is apparent that they 
are in a proliferation prone status and that any functional and 
genetic alteration that would remove or overcome such a 
block may result in increased and deregulated proliferation.
We also observed an unexpected up-regulation of Il6 and 
Il11 in AOM/DSS-treated Myd88/ mice that is associated 
with pSTAT3 expression in almost all nuclei of mucosal epi-
thelial cells. Although it is likely that the induction of these 
cytokines is dependent on the altered interaction with com-
mensal microbiota, in the absence of signaling through TLRs 
and IL-1Rs the availability of innate receptors available for 
signaling is reduced, but the engagement of cytoplasmic   
receptors, such as the NODs which are known to be associated 
with IBD and colon carcinoma in humans, remains a likely 
possibility.  The  phosphorylation  of  STAT3  is  most  likely 
downstream of IL-6 and IL-11, which are known mediators 
Importantly,  in  contrast  to  the  high  susceptibility  that 
Il18/ mice exhibited in response to DSS, we confirmed 
the data of others (Dinarello, 2007) that demonstrated that 
the mice were resistant to trinitrobenzene sulfonic acid (TNBS)–
induced colitis (unpublished data), indicating that IL-18 has a 
pathogenic role in immune-mediated colitis, but it has a pro-
tective role in the repair of mucosal damage in DSS-induced 
ulcerative colitis.
DISCUSSION
Several studies support a causative link between chronic   
inflammation and cancer, and the identification of inflamma-
tory pathways that contribute to carcinogenesis is of critical 
importance for cancer prevention and treatment. Pathways 
that use MyD88 have been implicated in the promotion of 
cancer in several mouse carcinogenesis models. In this paper, 
we show that under chronic colitis conditions induced by 
DSS-induced mucosal damage, MyD88 has a protective role 
in colon cancer.
The analysis of gene expression profile after AOM/DSS 
treatment in the colon of Myd88/ mice compared with 
WT mice generated informative results that, even if reflecting 
global gene expression in the colon tissue and not exclusively 
in epithelial cells, allowed us to propose possible mechanisms 
explaining the increased susceptibility of Myd88/ mice to 
CAC. In response to DSS-induced mucosal damage, the repair 
Figure 7.  Il18-deficient mice exhibit 
enhanced expression of mitogenic/  
inflammatory cytokines and STAT-3  
phosphorylation after AOM/DSS treatment. 
Cohorts of 8–10 WT and Il18/ mice per 
group were injected i.v. with AOM on day 0, 
followed by 3 d of DSS administration in 
drinking water. Thereafter, colons were  
resected, RNA was extracted, and RT-PCR was 
performed using specific primers for the  
indicated genes. The gene expression was 
normalized to Gapdh levels, and the expres-
sion of each gene relative to untreated WT 
mice is depicted (A). Tissue sections were 
stained for pSTAT3. Photomicrographs of 
representative sections from the respective 
groups are shown at 200× magnification. 
Protein extracts were analyzed by Western 
blotting for COX-2, STAT3, and pSTAT3 expres-
sion. Gapdh was used as a control (C). Quanti-
fication of colonic epithelial cell proliferation 
and apoptosis was performed in tissue  
sections stained with Ki67 or ApopTag anti-
bodies. The number of proliferating cells per 
crypt and the number of apoptotic cells/field 
are shown. The data shown in A–D correspond 
to a representative experiment out of two 
performed. Data represent means ± SE.  
*, P < 0.05; **, P < 0.01.JEM VOL. 207, August 2, 2010 
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response to DNA damage induced either by AOM or by the 
inflammatory mediators.
IL-18 (IL1F4) is a member of the IL-1 family that, similarly 
to IL-1, is translated as a pro-cytokine that requires processing 
by caspase-1 activated by the inflammasome. IL-18 was origi-
nally described as an inducer of IFN- acting mostly by am-
plifying the effect of other IFN- inducers such as IL-12. 
Thus, IL-18 was originally considered a Th-1–inducing cyto-
kine but it was later found that it can also enhance the pro-
duction of other cytokines, including Th-2 cytokines, and 
thus it has a much broader effect than originally thought. IL-18 
binds to a two-chain receptor that requires the adapter MyD88 
for signal transduction, similarly to all the other members of 
the IL-1 family. The functions of IL-18 are complex and their 
possible contribution to the maintenance of chronic inflamma-
tion in the intestine is unclear. Polymorphism in the gene 
encoding IL-18Rb has been associated with IBD (Zhernakova 
et al., 2008), whereas genetics data on polymorphism of the 
Il18 gene promoter have been controversial (Rodriguez-Bores 
et al., 2007). Several studies have associated circulating or local 
IL-18 with IBD severity, suggesting that IL-18 could be an 
effector cytokine in IBD (Dinarello, 2007). Early studies 
using Il18- or Caspase-1–deficient mice or blocking IL-18 
with antibodies or IL-18 binding protein have indicated that 
IL-18 is required for TNBS- or DSS-induced colitis (Dinarello, 
2007). However, studies in skin wound healing have demon-
strated an important role of IL-18 in the early phase of skin 
wound repair (Kämpfer et al., 2000). Similarly, other studies, 
unlike the results of some of the early studies, reported that 
Il18- or Il18R-deficient mice are more susceptible rather 
than resistant to DSS-induced colitis (Takagi et al., 2003; 
Reuter and Pizarro, 2004). Recently, it has been shown that 
mice deficient for the Nalp3 inflammasome or the inflamma-
some components Asc and caspase 1 (Dupaul-Chicoine et al, 
2010; Zaki et al., 2010) are very susceptible to DSS-induced 
acute colitis and this susceptibility has been attributed, at least 
in part, to decreased production of IL-18 on the basis of the 
ability of exogenously administered recombinant IL-18 to par-
tially protect the mice. We now report that not only are Il18/ 
and Il18r1/ mice more susceptible to AOM/DSS colitis 
with a phenotype that mimics, although it is milder, that of 
the Myd88/ mice but also that similar to the Myd88/, 
Il18/, and Il18r1/ mice are much more susceptible to 
CAC than WT mice. Il1r1/ mice were not significantly dif-
ferent from WT mice. As a control, we also tested the suscepti-
bility of Il18/ mice to TNBS-induced colitis, confirming the 
previously reported data (Dinarello, 2007) that in an immune   
T cell–mediated type of experimental colitis, IL-18 is an effector 
molecule probably required for optimal T cell response.
The phenotype observed in Il18/ and Il18r1/ mice 
mimics that of the Myd88/ mice, although the colitis was 
less severe and the development of colon polyps was slower 
and not as aggressive. In both deficient strains, the DSS colitis 
was characterized by severe bleeding and extensive erosion, 
likely reflecting that both genes are required for homeostatic 
control of the colon epithelium and for efficient repair upon 
of gastrointestinal inflammation and tumorigenesis, both of 
which are induced by and signal through STAT3, likely es-
tablishing a self-activating loop (Atreya and Neurath, 2008; 
Ernst et al., 2008). We observed enhanced expression of several 
known STAT3-dependent genes (Yu et al., 2009) in addition to 
Il6 and Il11 in AOM/DSS-treated Myd88/ mice, including 
Cox2, Hif1a, and several metalloproteases. STAT3 has also 
been reported to prevent TGF- signaling by inducing the 
suppressor Smad-7 (Jenkins et al., 2005), which is similar to 
what we have observed in our system. STAT3 activation in 
both epithelial cells and in stromal and infiltrating cells has 
been shown to regulate the tumor inflammatory environment 
as well as to have direct effects on the tumor itself by inducing 
antiapoptotic, proangiogenic, and proproliferative gene ex-
pression programs (Grivennikov et al., 2009; Yu et al., 2009). 
In contrast with the enhanced expression of the IL-6 family 
cytokines and the STAT3-dependendent genes, IFN- and 
many IFN-dependent genes were less induced in Myd88/ 
mice compared with WT mice. Our findings in the AOM/
DSS system are in striking contrast with the data observed in 
Apcmin/+ mice in which decreased IL-6, STAT3 phosphory-
lation, and STAT3-dependent gene expression were reported 
in the absence of MyD88 (Rakoff-Nahoum and Medzhitov, 
2007). This observation points to the fact that the mucosal 
damage induced by DSS in Myd88/ mice, with the conse-
quent exposure to commensal microbiota resulting in enhanced 
migration of bacteria to the mesenteric lymph nodes (Vaishnava 
et al., 2008), is likely responsible for a dramatically different 
state of inflammation compared with carcinogenesis models 
not associated with alteration of mucosal integrity.
Unlike in most WT mice in which polyps are not observed 
until after the third or fourth cycle of DSS and the majority 
of those are benign adenomas, in Myd88/ mice polyps are 
induced after a single DSS cycle and most of the tumors 
progress to aggressive and invasive adenocarcinomas that 
cause death starting at 2 mo after treatment. This suggested 
that in Myd88/ mice, the polyps may have a higher frequency 
of oncogenic mutations. Indeed, when we analyzed by PCR 
and sequencing of total DNA from excised polyps we were 
able to detect degradation-blocking mutations in exon 3 of 
-catenin in one-third of the polyps excised from Myd88/ 
mice, but none in those from WT mice. Because the initiating 
mutations in this model are induced by the mutagen AOM, 
we  analyzed  whether  defects  in  DNA  repair  mechanisms 
could be present in the Myd88/ mice. Indeed, we found 
that a large number of genes encoding factors involved in 
DNA repair were expressed at significantly lower levels in 
the colon of Myd88/ mice than in WT mice after AOM/
DSS treatment. It is of interest that all the DNA damage re-
sponse genes that we have observed to be decreased in the 
mice corresponded to genes that have been reported to be 
frequently mutated in human colon cancer or in familiar he-
reditary nonpolyposis colon cancer syndrome (Bartek et al., 
2007; Lynch et al., 2009). It is therefore plausible that one of 
the mechanisms of the increased susceptibility to AOM/DSS-
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of their inability to signal through TLR4-MyD88. The role of 
TLR5 and TLR9 on CAC remains to be elucidated, although it 
is possible that TLR5 plays a protective role because Tlr5   
deletion resulted in the development of spontaneous colitis   
(Vijay-Kumar et al., 2007). Tlr9-deficient mice are more resis-
tant to DSS-induced colitis (Obermeier et al., 2005), but 
TLR9 ligands protect mice from colitis by inducing type I IFN 
production (Katakura et al., 2005). Obviously, a large number 
of other TLRs are upstream of MyD88 (up to 15 in mammals). 
Several other members of the IL-1 family, in addition to IL-1, 
IL-1, and IL-18, could possibly be involved and, by acting on 
the same or different cell types in the colon, might act synergisti-
cally or antagonistically in determining the susceptibility to colitis   
and CAC. Finally, it remains to be identified in which cell types 
MyD88 signaling is important for colitis and CAC and, in the 
case of IL-18, which cells are producing and responding to it.
MATERIALS AND METHODS
Mice. Myd88/, Il1r1/, Il18/, and Il18r1/ mice were maintained 
in a specific pathogen-free (including helicobacter and parvovirus) envi-
ronment, and generally used between 6 and 10 wk of age. All strains 
were backcrossed to obtain at least 98% congenicity to either B6J or 
B6NCr background. As control groups, either littermates or WT mice of 
identical background were used. Animal studies were approved by the 
Institutional Animal Care and Use Committee (IACUC) of National 
Cancer Institute (Frederick, Maryland) and were conducted in accor-
dance with the IACUC guidelines and the National Institutes of Health 
Guide for the Care and Use of Laboratory. (National Institutes of Health 
Publication No. 86–23, 1985).
AOM/DSS  model  of  chronic  colitis. Mice 6–8 wk of age were   
injected i.p. with 10 mg/kg AOM in 0.2 ml saline. 1 wk after AOM ad-
ministration, DSS at 2% was administered in the drinking water for five 
consecutive days. Thereafter, mice received reverse osmosis water. Up to 
four  DSS  cycles  were  administered  with  intervals  of  16  d  on  water   
between cycles. In some experiments, 10 mg/kg AOM was administered 
i.p. once a week for six consecutive weeks. During the course of the ex-
periment, mice were monitored for body weight, rectal prolapse, diar-
rhea, and macroscopic bleeding, as well as occult blood by hemoccult 
(Beckman Coulter).
At the time of harvest, colons were resected, flushed with PBS, opened 
longitudinally, and measured. Polyps were counted using a stereomicro-
scope. Colon sections were fixed in formalin or snap frozen. In some experi-
ments, polyps were harvested individually and frozen in liquid nitrogen.
Gene expression analysis by microarrays and real-time quantitative 
RT-PCR. Total RNA was extracted from colon sections and gene expres-
sion was analyzed by whole genome mouse microarray (Affymetrix) or by 
quantitative RT-PCR as detailed in the supplemental material.
Mutation analysis. PCR products were purified on the Mag-Bind EZ 
Pure kit (Omega Bio-Tek). The product was then sequenced bidirec-
tionally  using  BigDye  Terminator  (version  1.1;  Applied  Biosystems). 
The PCR amplification oligonucleotides were used as sequencing prim-
ers.  Unincorporated  terminators  were  removed  from  the  sequencing 
product using the Mag Bind SE DTR kit (Omega Bio-Tek) before elec-
trophoresis on a sequencer (ABI3730; Applied Biosystems). Sequences 
were analyzed using Mutation Surveyor software (SoftGenetics, LLC). 
Somatic mutations were identified in samples where complementary mosaic 
peaks were present at the mutation site in both directions. The default 
settings of Mutation Surveyor (mutation score > 5, peak height > 500, 
overlap > 0.2) were used to determine mosaic peak presence.
injury. However, unlike in Myd88/ mice, in Il18/ mice 
the  enterocyte  proliferation  or  apoptosis  after  AOM/DSS 
treatment was not significantly altered and COX-2 expression 
was not enhanced.
In both Myd88/ and Il18/ mice, the inflammatory 
response to AOM/DSS treatment is characterized by an en-
hanced  production  of  IL-6  family  cytokines  and  STAT3 
phosphorylation  associated  with  a  decreased  expression  of 
IFN- and of IFN-dependent genes. Thus, the enhanced 
susceptibility to carcinogenesis in these mice is surprising be-
cause in other models of inflammation-induced colon carcino-
genesis, for example, in Socs1-, Sigirr-, and Caspase-12–deficient 
mice, in which there is an enhanced inflammatory response 
with inflammasome hyperactivation and/or increased signal-
ing through the TOLL/IL-1 and IFN- receptors, the in-
creased  susceptibility  to  colon  carcinogenesis  is  associated 
with an increased production of proinflammatory cytokines 
including IFN- (Hanada et al., 2006; Xiao et al., 2007;   
Dupaul-Chicoine et al., 2010). In particular, in the Socs-1–
deficient mice, IFN- was shown to be required for sponta-
neous colon tumor formation even when the IL-6/STAT3 
axis was still active (Hanada et al., 2006). These data make it 
unlikely that the increased susceptibility of Myd88/ and 
Il18/ mice to colon carcinogenesis might exclusively be 
the result of the lack of an immunosurveillance effect of adaptive 
immunity and IFN- (Dunn et al., 2006), particularly when 
it is considered that Rag/ immunodeficient mice have re-
duced rather than increased susceptibility to colon carcino-
genesis (unpublished data).
Thus, it appears that the increased susceptibility of Il18/ 
mice to colitis and CAC in the AOM/DSS model may be 
dependent  on  partially  overlapping  mechanisms  in  both 
MyD88- and Il18-deficient mice. The deficient expression of 
either gene appears to be responsible for deviation of the inflam-
matory response, as well as alteration of homeostatic and mu-
cosal repair mechanisms and the host interaction with the 
commensal microbiota (Vaishnava et al., 2008; Dupaul- 
Chicoine et al., 2010), resulting in increased susceptibility to 
carcinogenesis. Inability to signal through the IL-18R may 
represent the central mechanism responsible for the phenotype 
of Myd88/ mice, although the milder phenotype of Il18/ 
compared with Myd88/ mice suggests that other MyD88-
coupled receptors may act in concert with IL-18 to minimize 
carcinogenesis. Alternatively, signaling through the IL-18R 
might be the major factor responsible for carcinogenesis pro-
tection,  but  the  lack  of  signaling  through  other  MyD88- 
coupled receptors, on epithelial or other cells, may contribute 
to altering the colon microenvironment and minimizing the 
effect of the IL-18 signaling deficiency. Our data with Tlr2-
deficient mice seems to exclude a major role for this receptor 
in our model, in contrast to others who have reported that 
Tlr4/ mice in part reproduce the phenotype of Myd88/ 
mice in terms of inability to efficiently repair the colon mucosa 
upon DSS-induced injury. However, Tlr4/-deficient mice 
were resistant to CAC (Fukata et al., 2007), thus indicating 
that the susceptibility to CAC in Myd88/ mice is not a result JEM VOL. 207, August 2, 2010 
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Real-time quantitative RT-PCR. The cDNA was prepared from 500 ng 
of total RNA according to the protocol for SuperScript II Reverse transcription 
(Invitrogen). For each sample, real-time quantitative RT-PCR was then 
performed using 12.5 ng cDNA, the SYBR Green PCR Master Mix (Applied 
Biosystems), and the forward and reverse primers, at a final concentration of 
0.3 µM, in a sample volume of 25 µl. The primers, which are listed in Table S1, 
were designed using Primer 3.0 software from mRNA sequences submitted 
to GenBank and checked in BLAST to confirm the total gene specificity. 
PCR was performed using a StepOnePlus machine (Applied Biosystems) 
under the cycling conditions required in the protocol for SYBR Green PCR 
Master Mix. The expression of candidate genes in each group of mice was nor-
malized to Gapdh to obtain a Ct value and to calculate a 2^(mean Ct). 
Data represent 6 and 10 different mice per group and are relative to the levels of 
expression of Gapdh in the untreated WT mice. For statistical analysis, a two-
tailed Mann Whitney test was performed comparing the Ct values.
Online supplemental material. In Fig. S1, the susceptibility of MyD88-
deficient  mice  to  AOM/DSS-induced  colitis  and  CAC  is  maintained 
when compared with corresponding littermate WT mice. Fig. S2 shows 
that Myd88/ mice are resistance to the development of colonic polyps 
in response to AOM or DSS treatment alone. Fig. S3 shows an unsuper-
vised heat map of genes differentially expressed among treated WT versus 
treated Myd88/ mice. Fig. S4 shows that AOM/DSS treatment enhances 
the expression of genes involved in the EGFR and B-catenin pathways 
on Myd88/ mice compared with WT mice. Fig. S5 shows that Il18/ 
mice are highly susceptible to DSS colitis. Fig. S6 shows that Il18r1/ 
mice are susceptible to AOM/DSS administration, similar to Il18/ mice. 
Table S1 shows real-time PCR primer sequences and experimental con-
ditions.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20100199/DC1.
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Immunohistology. Immunohistochemical staining was performed on for-
malin-fixed paraffin-embedded tissues using rabbit mAb to phospho-STAT3 
(Tyr705; clone D3A7; 1:1000; Cell Signaling Technology), rabbit anti–mouse 
COX-2 (1:1,000; Cayman Chemical), and rabbit anti-Ki67 (1:10,000; Vector 
Laboratories). The corresponding secondary antibodies were obtained from 
Vector Laboratories. Apoptosis was detected using the ApopTag kit (Millipore). 
For detection, the Vectastain ABC kit (Vector Laboratories) and diamino-
benzidine (Sigma-Aldrich) were used. The distal and middle sections of colon 
were assessed for inflammation using a semiquantitative score (0–15) system 
as follows: distribution of inflammation, 0 = none, 1 = focal, 2 = multifocal, 
3 = diffuse; severity of inflammation, 1 = mild, 2 = moderate, 3 = severe; 
extent of inflammation, 1 = mucosal only, 2 = extends to submucosa, 3 = ex-
tends to muscle; ulceration, 0 = none, 1 = focal/locally extensive, 2 = multifo-
cal, 3 = diffuse/extensive; and degree of necrosis, 0 = none, 1 = mild, 2 = 
moderate, and 3 = severe. Total disease score per mouse was calculated by 
adding each parameter.
SDS-PAGE and immunoblotting. Colon sections were lysed in buffer 
containing 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM 
NaCl, 10 mM Tris HCl, pH 7.4, 1 mM EDTA, 1 mM sodium orthovana-
date, 0.5 mM PMSF, and complete protection protease inhibitors (Boeh-
ringer Mannheim). Protein extracts were centrifugated at 14,000 rpm for   
15 min at 4°C. Total protein was determined, samples were subjected to 
SDS-PAGE, and the proteins were transferred into PDF membranes. After 
blocking (1% BSA or 5% milk, 2 h, 4°C), the membranes were stained using 
rabbit mAb to phospho-STAT3 (1:1,000) and rabbit anti–mouse STAT-3 
(1:1,000; Cell Signaling Technology), rabbit anti–mouse COX-2 (1:200), 
and rabbit mAb to GAPDH HRP conjugated (1:1,000; Cell Signaling Tech-
nology). Membranes were exposed to the corresponding secondary antibodies 
and then washed and developed by ECL (GE Healthcare).
Microarray performance and statistical analysis. Total RNA was   
extracted using reagent (QIAGEN) according to the manufacturer’s instruc-
tions. RNA was digested using the RNase-Free Dnase set and amplified into 
antisense RNA (aRNA) according to the Affymetrix gene expression proto-
col. The quality of both total RNA and secondarily amplified RNA was 
tested using a Bioanalyzer 2000 (Agilent Technologies). Test aRNA was 
loaded into whole genome mouse arrays 430 2.0 (Affymetrix) and hybrid-
ized overnight in a hybridization oven. Posthybridization arrays were labeled 
using a fluidics wash (Affymetrix) and stain station and were immediately 
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